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Abstract
Introduction: HIV and tuberculosis (TB) remain leading causes of preventable death in low- and middle-income countries
(LMICs). The World Health Organization (WHO) recommends HIV testing for all individuals with TB symptoms, but implemen-
tation has been suboptimal. We conducted a systematic literature review and meta-analyses to estimate HIV and TB preva-
lence, and short-term (two to six months) mortality, among adults with TB symptoms at community- and facility level.
Methods: We searched Embase, Global Health and MEDLINE databases, and reviewed conference abstracts for studies
reporting simultaneous HIV and TB screening of adults in LMICs published between January 2003 and December 2017.
Meta-analyses were performed to estimate prevalence of HIV, undiagnosed TB and mortality risk at different health system
levels.
Results: Sixty-two studies including 260,792 symptomatic adults were identified, mostly from Africa and Asia. Median HIV
prevalence was 19.2% (IQR: 8.3% to 40.4%) at community level, 55.7% (IQR: 20.9% to 71.2%) at primary care level and
80.7% (IQR: 73.8% to 84.6%) at hospital level. Median TB prevalence was 6.9% (IQR: 3.3% to 8.4%) at community, 20.5%
(IQR: 11.7% to 46.4%) at primary care and 36.4% (IQR: 22.9% to 40.9%) at hospital level. Median short-term mortality was
22.6% (IQR: 15.6% to 27.7%) among inpatients, 3.1% (IQR: 1.2% to 4.2%) at primary care and 1.6% (95% CI: 0.45 to 4.13,
n = 1 study) at community level.
Conclusions: Adults with TB symptoms have extremely high prevalence of HIV infection, even when identified through com-
munity surveys. TB prevalence and mortality increased substantially at primary care and inpatient level respectively. Strategies
to expand symptom-based TB screening combined with HIV and TB testing for all symptomatic individuals should be of the
highest priority for both disease programmes in LMICs with generalized HIV epidemics. Interventions to reduce short-term
mortality are urgently needed.
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1 | INTRODUCTION
Tuberculosis (TB) and human immunodeficiency virus (HIV)
are the two leading causes of adult infectious disease deaths
worldwide. In 2016, there were 1.7 million deaths due to TB
globally, including 0.4 million deaths among HIV-positive indi-
viduals [1]. Reducing the high mortality from HIV-related TB
has become an increasingly high priority of The Joint United
Nations Programme on HIV/AIDS (UNAIDS) and The United
States President’s Emergency Plan for AIDS Relief (PEPFAR)
programmes, and the recently ratified End TB Strategy
includes a 35% reduction in TB deaths by 2025 among other
targets [2].
Early diagnosis and treatment are key components of both
HIV and TB programmes [3]. HIV testing is being scaled-up as
countries work towards the UNAIDS “90-90-90” HIV diagno-
sis and care targets for 2020 [4]. Similarly, the End TB Strat-
egy places increased emphasis on systematic screening for TB,
including facility attendees and high risk communities, as part
of early TB diagnosis [4]. Guidelines for TB/HIV collaborative
activities released by the World Health Organization (WHO)
in 2004 were updated in 2012 [5]. The 2004 guidelines
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focused on HIV testing and care for diagnosed TB patients
and TB screening and prevention as part of HIV care, with
annual reporting requirements. The 2012 guidelines recom-
mend HIV testing among patients with suspected TB, noting
high HIV prevalence and suboptimal service integration for
this group, but without good quality of evidence, additional
data reporting recommendations, or consideration of HIV test-
ing in the context of TB screening programmes [5].
TB patients undergoing treatment in national TB pro-
grammes are at high risk of death, especially if HIV positive
[6,7]. A 2011 meta-analysis estimated that 18.8% (95% confi-
dence interval [CI]: 14.8% to 22.8%) of HIV-positive and 3.5%
(95% CI: 2.0% to 4.9%) of HIV-negative TB patients die dur-
ing TB treatment [7,8]. Adults with symptoms such as cough
with or without confirmed TB disease in high HIV prevalence
settings also face a high risk of early mortality, with HIV infec-
tion a risk factor for worse outcomes [9]. Despite the 2012
recommendation and suggestions of similar HIV prevalence
and short-term mortality risks as notified TB patients, routine
management of adults with TB symptoms in health services
remains suboptimal with missed opportunities for HIV testing
and referral for ART [9]. In addition, monitoring for HIV test-
ing and linkage to ART is still not well established among
patients with TB symptoms, with neither HIV nor TB pro-
grammes reporting coverage or outcomes. Accurate estimates
of HIV and TB burden and risk of death among adults with
symptoms of TB may help policymakers, researchers and
implementers to prioritize appropriate collaborative interven-
tions at the different levels of the healthcare system. We,
therefore, set out to systematically summarize HIV preva-
lence, active TB prevalence and mortality risk among people
with symptoms of TB (with or without confirmed TB disease)
identified at community level (the general population) and in
health facilities in low- and middle-income countries (LMICs)
with different underlying burden of HIV and TB.
2 | METHODS
2.1 | Search strategy
In accordance with our published protocol (PROSPERO ID:
CRD42015021944), we searched MEDLINE, Embase and
Global Health electronic databases using a predefined search
strategy (Table S1) for studies reporting outcomes of HIV and
TB screening among adults identified in the community or
during health facility attendance in LMICs that were published
between 1 January 2003 and 31 December 2017. The start
of the literature search was set in 2003 because it is the year
the ART scale-up commenced in many LMICs. We additionally
hand-searched abstracts from the Union World Conferences
on Lung Health and International AIDS Society (IAS) Confer-
ences from January 2014 to December 2017.
2.2 | Eligibility criteria
Studies were eligible for inclusion if they offered participants
systematic screening for HIV at the time of TB screening.
Acceptable TB screening algorithms comprising either symp-
tom screening followed by microbiological confirmatory testing
for active TB, or universal microbiological testing for TB, as
well as HIV testing. We included randomized controlled trials
(RCTs), cohort studies, cross-sectional studies, TB prevalence
surveys, studies of evaluation of new TB diagnostic tests and
published reports of programmatic activities, but excluded
commentaries, editorials, case reports, case series, economic
analyses and qualitative studies.
Studies conducted in countries defined to be low- or middle
income by the World Bank lending groups in 2016 were
included. We included studies that recruited only adults
(≥16 years), or where both children and adults were included
and age-disaggregated data were reported. We excluded stud-
ies that reported only a preselected, unrepresentative group
of participants, including diagnosed TB or HIV-positive
patients only, sputum smear-negative patients, TB household
contacts, participants with suspected multidrug-resistant TB,
miners and pregnant women.
Studies were imported into an EndNote X7 database and
duplicates were removed. MN screened the titles and
abstracts of all studies against inclusion and exclusion criteria,
and the full text of potentially eligible studies were reviewed
in duplicate by MN and AGW against inclusion and exclusion
criteria using a predesigned electronic assessment form. Dis-
crepancies were resolved by discussion between the review-
ers, with arbitration by a third reviewer (PM) in case of
disagreement.
2.3 | Data extraction
MN and AGW extracted data from selected studies using a
previously piloted electronic data extraction form; inconsisten-
cies were resolved by discussion. For each study, we extracted
the author name, year, country and setting, and we described
details of the TB and HIV screening algorithms used. The fol-
lowing data were extracted for main outcomes: total number
of participants, number screened for TB symptoms and num-
ber screening positive for TB symptoms. For adults with TB
symptoms, we then extracted the numbers screened and diag-
nosed with HIV and TB and the number of deaths.
2.4 | Assessment of study quality
For assessment of methodological quality, RCTs were distin-
guished from non-randomized studies (see Supplementary
material). For RCTs, the Cochrane Collaboration’s Tool for
Assessing Risk of Bias was used. For non-randomized studies,
a modified version of the Newcastle-Ottawa Scale was used
to assess selection of participants and methods of assessment
of each of the three outcomes (Table S2). For the HIV preva-
lence outcome, we assessed uptake of HIV testing and the
quality of the diagnostic algorithm used; studies relying only
on participants’ verbal report were classified as having high
risk of bias. Similarly, for the TB prevalence outcome, we
assessed uptake of testing and if TB disease was bacteriologi-
cally confirmed (i.e. based on sputum smear microscopy,
Xpert MTB/RIF or culture testing) or clinically diagnosed
(when classified as TB patient without bacteriological confir-
mation). For mortality risk, we assessed methods of ascertain-
ment of deaths (i.e. hospital/study record, verbal autopsy or
vital registration) and the completeness of follow-up of the
cohorts. For each study, the overall risk of bias for each out-
come was categorized as low-, high- or unclear depending on
the assessment of the domains above.
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2.5 | Definitions
We classified participants symptomatic of TB as either having
chronic cough (defined as ≥2 weeks as commonly used in
community surveys) or as having ≥1 symptom in the WHO-
recommended four-symptom screening tool (current cough of
any duration, fever, night sweats, or weight loss).
We defined four levels of healthcare. The community level
encompassed the general population that is studies recruiting
adults from households or temporary mobile service in resi-
dential areas (excluding those in schools, prisons or other
institutions). The primary care level included general practi-
tioner services and health centres. The hospital-level category
included studies on inpatients admitted to a ward and stayed
at least one night in hospital. An additional category of mixed
setting was used to define studies that included participants
from more than one level that is both primary care clinics and
hospitals (without disaggregated data), or for participants
recruited at specialist outpatient clinics.
For each study, we defined national adult (aged 15 to
49 years old) HIV prevalence by year and country using
UNAIDS estimates. For studies spanning more than one year,
estimates were based on the middle year, if study covered an
even number of years the average national prevalence of the
two middle years was used. National incidence of TB was esti-
mated from data reported in the WHO global TB reports for
each year, and categorized as: low (<30 per 100,000), moder-
ate (30 to 100 per 100,000), medium (100 to 300 per
100,000) and high (>300 per 100,000) [10]. Geographical dis-
tribution of studies was categorized based on WHO regions
[11]. For mortality outcome, short-term or early mortality was
defined as deaths occurring in the first six months of follow-
up among those with TB symptoms.
A case of TB disease diagnosed after recruitment was
defined as report by a study of a bacteriologically confirmed
case (at least one positive sputum smear microscopy sample,
positive culture for Mycobacterium tuberculosis (MTB), or a
positive Xpert MTB/RIF result) or a clinically diagnosed case
(when TB treatment was initiated without bacteriological con-
firmation).
2.6 | Statistical analyses
The primary outcomes of the study were: HIV prevalence (the
number of participants with confirmed HIV infection divided
by the total number with TB symptoms), prevalence of active
TB (the number with active TB divided by the number with
TB symptoms) and mortality risk (the number of participants
confirmed to have died by six months divided by the number
with TB symptoms). We stratified analyses by level of health-
care (community, primary care, mixed and hospital inpatients).
For HIV and TB prevalence outcomes, we undertook subgroup
analyses by geographical region, type of TB symptoms,
national HIV prevalence and TB incidence. For HIV, we also
determined the number needed to screen (NNS) to detect a
newly diagnosed HIV-positive individual. The NNS for TB was
not conducted because it was discussed in detail in a 2013
systematic literature review by Shapiro et al. [12].
We assessed heterogeneity between studies using the I2
statistic. Meta-analyses were conducted using random effects
models to estimate weighted summary outcome measures and
95% CI for each of the three outcomes, stratified by level of
healthcare. Arcsine transformation of proportions was imple-
mented in the calculation of pooled prevalence to handle zero
or unitary values. When it was not appropriate to conduct
meta-analyses (i.e. if substantial heterogeneity with an
I2 ≥ 50%) [13], prevalence estimates were summarized as
medians and interquartile ranges (IQR).
Meta-regression analyses were performed to examine asso-
ciations between HIV and TB prevalence and geographical
region, group of TB symptoms, country-level HIV prevalence
and country-level TB incidence. Characteristics showing strong
association with respective outcomes on univariate meta-
regression were included in the multivariate meta-regression.
The variable TB symptom type (chronic cough only or ≥1
symptom from the WHO tool) was included in the model a
priori. Due to the small number of studies reporting mortality,
meta-regression analyses were not conducted for this out-
come. Analyses were conducted using R version 3.2.3 (The R
Foundation for Statistical Computing, Vienna, 2016).
2.7 | Ethics statement
This review used published data and ethical review was not
required.
3 | RESULTS
3.1 | Characteristics of included studies
The search strategy identified 20,863 records, from which we
selected 289 eligible manuscripts (Figure 1). We included 59
manuscripts in the qualitative synthesis; 58 manuscripts
reported single-site studies and one manuscript reported on a
multisite study (four eligible sites were treated as individual
studies). The final number of studies included in the analysis was
62; all 62 for HIV prevalence outcome, 59 for TB prevalence and
11 for mortality risk (Figure 1). Common reasons for exclusion
included studies in preselected, unrepresentative populations
(68.7%, 158/230) and not presenting outcome data stratified by
presence of TB symptoms (20.9%, 48/230) ( Table S3).
In keeping with our requirement for systematic HIV testing
in parallel with TB investigations, most studies were from the
African region (51/62, 82.3%), with the largest number from
South Africa (13/62, 21.0%) (Table 1). In total, studies
included 260,792 adults with TB symptoms, with one study
from India [14] contributing 115,308 participants.
Twelve (12/62, 19.4%) studies were conducted at commu-
nity level, 26/62 (41.9%) at primary care level, 9/62 (14.5%)
at hospital level (inpatients) and 15/62 (24.2%) were con-
ducted in mixed settings (Table 1). Studies at community level
were cross-sectional [15-19] and cohort in design (Table 2)
[20-22]. Studies at primary care level were either diagnostic
evaluations [23-30], programme evaluations [31-33] or other
cross-sectional designs [34-37]. Studies among hospital inpa-
tients were predominantly diagnostic evaluations [38-41].
3.2 | Quality of included studies
For HIV prevalence outcome, 47/62 (75.8%) of the studies
had low risk of bias while 15/62 (24.2%) had high or unclear
risk of bias (Supplementary material). Studies were
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categorized as having high risk of bias for the HIV prevalence
due to poor determination of HIV status (6/62, 9.7%)[22-
24,32,38,39]; unclear or low uptake of HIV testing (8/62,
12.9%)[18,23,34,42-45]; and not describing how HIV status
was determined (1/62, 1.6%) [38]. Most (53/59, 89.8%) stud-
ies had low risk of bias for the estimation of TB prevalence.
There were only 11/62 (17.7%) studies that reported on the
outcome of mortality; 63.6% (7/11) of them had high risk of
bias. Reasons for the high risk of bias were high loss to fol-
low-up rates, (4/11, 36.4%) [20,25,27,30], and not describing
how vital status was ascertained, (3/11, 27.3%) [40,46,47].
3.3 | Prevalence of HIV by level of health care
Of the total 260,792 adults with symptoms of TB reported in
62 included studies, 184,601 (70.8%) were successfully
screened for HIV. There was substantial variability in esti-
mated HIV prevalence (range: 0.5% to 100%) (Table 2 and
Figure S1). By level of care, the median HIV prevalence
among adults with TB symptoms was 19.2% (IQR: 8.3% to
40.4%, n = 12 studies) at community level, 55.7% (IQR: 20.9%
to 71.2%, n = 26 studies) at primary care level, 28.6% (IQR:
21.4% to 52.0%, n = 15 studies) in mixed settings, and was
80.7% (IQR: 73.8% to 84.6%, n = 9 studies) among hospital
inpatients (Table 3).
In univariate and multivariate meta-regression, HIV preva-
lence among adults with TB symptoms was significantly higher
in the following studies: among hospital inpatients, from the
African region, with high national HIV prevalence, and those
reporting chronic cough only (Table 3). Compared to adults
with TB symptoms in the community, those at higher levels of
care had higher HIV prevalence; adjusted prevalence ratio
(aPR) 1.32 (95% CI: 1.15 to 1.50) at primary care, aPR 1.29
(95% CI: 1.12 to 1.50) in mixed settings and aPR 1.66 (95%
CI: 1.40 to 1.97) among hospital inpatients. Adults with TB
symptoms from countries with higher HIV prevalence also had
higher HIV prevalence, aPR 1.45 (95% CI: 1.30 to 1.62).
Seven studies reported on the number of participants newly
diagnosed with HIV following screening (Table S6). At commu-
nity level, the number of adults with TB symptoms needed to
screen to detect one new HIV-positive individual was 11 in
Malawi [48], 4 in South Africa [19] and 121 in Rwanda [49].
Database searching
Embase (n = 7722)
Global Health (n = 5701)
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Full-text articles assessed for eligibility
(n = 289)
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Figure 1. PRISMA flow diagram for process of selecting included studies. (a) Reasons for exclusion are explained in supplementary material.
(b) One study, Boehme et al., was a multisite study (six sites), four sites were eligible; the total number of individual studies was 62. (c) Two
studies did not report on results of TB testing.
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In primary care clinics the NNS was 2 in Malawi [29] and Zim-
babwe [50], 4 in Zambia [51] and 30 in India (Table S6) [32].
3.4 | Prevalence of TB disease by level of
healthcare
There were 59 studies (155,167 adults with TB symptoms)
that reported on results of TB screening. In these studies,
estimated TB prevalence ranged from 0.8% to 71.9%
(Table 2). By level of healthcare, the median TB prevalence
was lowest at community level (6.9% [IQR: 3.3% to 8.4%,
n = 12 studies]), followed by primary care level (20.5% [IQR:
11.5% to 46.8%, n = 23 studies]), mixed settings (36.4% [IQR:
22.9% to 41.0%, n = 15 studies]) and hospital inpatients (34.8
[IQR:26.5% to 40.7%, n = 9 studies]) (Table 4).
On univariate analysis, neither high national HIV prevalence
(PR 1.05 [95% CI: 0.93 to 1.19]) nor high national TB inci-
dence (PR 1.08 [95% CI: 0.94 to 1.26]) was associated with
higher TB prevalence among adults with TB symptoms
(Table 4), although statistical power was limited by the small
number of studies from low HIV prevalence settings. In addi-
tion, there was no association with geographical region or
group of symptoms used (Table 4).
On univariate and multivariate analysis, TB prevalence was
higher in symptomatic adults identified in all of primary care
setting (aPR 1.27 [95% CI: 1.11 to 1.46]), mixed settings (aPR
1.44 [95% CI: 1.21 to 1.72]) and among hospital inpatients
(aPR 1.42 [95% CI: 1.21 to 1.64]) than those in the commu-
nity (Table 4). However, the 95% CI for TB prevalence ratios
overlapped at levels higher than community, therefore differ-
ences were not statistically significant (also see Figure 2).
3.5 | Mortality in adults with symptoms of
tuberculosis
Eleven studies were included for analysis of cumulative inci-
dence (risk) of mortality reported between two and
six months of follow-up; all were from Africa (Figure S2).
Given the small number of studies we did not attempt to dif-
ferentiate mortality by follow-up duration, instead considering
all as short-term mortality (i.e. up to six months). Short-term
mortality risk was highest among hospital inpatients, with a
median risk of death of 22.6% (IQR: 15.6% to 27.7%, n = 3
studies). Median risk of short-term death was substantially
lower among participants identified at primary care level
(3.1% [IQR: 1.2% to 4.2%, n = 6 studies]) and community
(1.6% [95% CI: 0.45 to 4.13], n = 1 study).
3.6 | Influence of study quality on estimates
There was no significant difference in the estimate of HIV
prevalence between low-quality studies (median 34.0% [IQR:
19.2% to 68.1%]) and high-quality studies (median 46.2%
[IQR: 20.3% to 69.7%]), prevalence ratio 0.98 (95% CI:
0.81 to 1.19) (Table S7). Similarly, there was also no differ-
ence in estimate of TB prevalence between low-quality
studies (median 15.4% [IQR: 8.9% to 28.9%]) and high-qual-
ity studies 22.1% (IQR: 11.1% to 39.8%), PR 0.89 (95% CI:
0.74 to 1.08) (Table S7). Notably, estimates of mortality
risk were mostly based on low-quality studies 54.5% (6/11),
representing the need for better quality studies for this
outcome.
4 | DISCUSSION
The main findings of this study, largely restricted to settings
with generalized HIV epidemics by our selection criteria of
studies reporting systematic HIV testing during investigation
of TB symptoms, demonstrate extremely high HIV prevalence
even for patients identified in the community during TB
prevalence surveys (median 19.2% HIV prevalence). HIV
prevalence was higher than TB prevalence in patients with TB
symptoms at every level in the health system. The prevalence
Table 1. Characteristics of included studies
Region Countries Studies
Level of care
Number with
TB symptomsCommunity Primary care Hospital inpatients Mixed
African region
Southern Africaa 5 27 4 15 6 2 37,285
East Africab 5 17 5 5 2 5 27,019
West Africac 3 6 1 1 1 3 4,775
Central Africad 1 1 0 1 0 0 49,832
SE Asia regione 2 8 0 4 0 4 122,237
W Pacific region 1 1 1 0 0 0 12,201
Americas 2 2 1 0 0 1 7,443
Total 19 62 12 26 9 15 260,792
aCountries are South Africa (studies=13), Botswana (2), Malawi (5), Zambia (4) and Zimbabwe (3).
bCountries are Ethiopia (5), Kenya (2), Tanzania (3), Uganda (6) and Rwanda (1).
cCountries are Guinea Bissau (2), Ghana (1), Nigeria (3).
dOne study from Democratic Republic of Congo.
eCountries are Thailand (3) and India (5), includes one large study from India with 115,308 participants.
SE Asia, South East Asia; W Pacific, Western Pacific.
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Table 2. TB diagnostic procedures of included studies
Country, author,
yeara Study design Study description
Participant
Eligibility criteria
TB diagnosis
algorithm
Participants
with
symptoms HIV prev. TB prev.
n n (%) n (%)
Community level
Cambodia, Lorent
(2012) [18]
Cross-sectional
study
Active TB case
finding (door to
door strategy)
Any TB
symptoms
Microscopy
(fluorescence),
Xpert MTB/RIF,
culture
(LJ) + species ID
and DST
12,201 319 (2.6) 774 (6.3)
Ethiopia, Deribew
(2012) [17]
Cross-sectional
study
Regional TB
prevalence survey
Cough ≥2 weeks Microscopy
(fluorescence,
ZN), culture (LJ)
+ species ID
482 5 (0.9) 17 (2.9)
Guinea Bissau,
Bjerregaard-
Andersen (2009)
[22]
Cross-sectional
study
Regional TB
prevalence survey
Cough or any
two other TB
symptoms
ZN microscopy,
CXR
116 24 (20.7) 8 (6.9)
Malawi, Nliwasa
(2016) [20]
Cohort study
(individuals
with chronic
cough vs no
cough)
Assessing TB yield
and mortality risk
Cough ≥2 weeks Microscopy
(fluorescence),
Xpert MTB/RIF,
culture (MGIT)
+ species ID
178 56 (31.5) 6 (3.4)
Haiti, Rivera (2017)
[65]
Cross-sectional
study
Active TB case
finding (door to
door strategy)
Cough ≥2 weeks CXR, Microscopy,
Xpert MTB/RIF,
5598 528 (9.4) 1,000 (17.9)
Rwanda, 2014 [49] Cross-sectional
study
National TB
prevalence survey
Cough (any
duration) or
abnormal CXR
Microscopy
(fluorescence),
culture (MGIT)
+ species ID
4747 218 (4.6) 54 (1.1)
South Africa,
Kranzer (2012)
[19]
Cross-sectional
study
Mobile multi-disease
screening service
Any TB
symptoms, or
if HIV positive
or diabetic
Microscopy
(fluorescence),
culture (MGIT)
+ species ID
1385 758 (54.7) 103 (7.4)
Tanzania, 2013 [42] Cross-sectional
study
National TB
prevalence survey
Cough ≥2 weeks
or abnormal
CXR
Microscopy
(fluorescence),
culture (MGIT)
+ species ID
6271 782 (12.5) 149 (2.4)
Uganda, Sekandi
(2014) [21]
Cross-sectional
study
Active TB case
finding (door to
door strategy)
Cough ≥2 weeks ZN microscopy and
culture (LJ)
199 82 (41.2) 39 (19.6)
Uganda, 2017 [66] Cross-sectional
study
National TB
prevalence survey
Cough ≥2 weeks
or abnormal
CXR
ZN microscopy,
Xpert MTB/RIF
and culture (LJ).
4386 417 (9.5) 160 (3.6)
Zambia, Ayles
(2009) [15]
Cross-sectional
study
TB prevalence
survey – selected
area
All adults in rural
and urban
communities
ZN microscopy,
culture (MGIT &
LJ) + species ID
578 230 (39.8) 34 (5.9)
Zimbabwe, Corbett
(2010) [16]
Cross-sectional
study
TB prevalence
survey – selected
area
All adults from
randomly
selected
households
Microscopy
(fluorescence),
culture (LJ)
+ species ID
333 153 (45.9) 37 (11.1)
Primary care
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Table 2. (Continued)
Country, author,
yeara Study design Study description
Participant
Eligibility criteria
TB diagnosis
algorithm
Participants
with
symptoms HIV prev. TB prev.
n n (%) n (%)
DR Congo,
Yotebieng (2013)
[67]
Cross-sectional
study
Evaluation of HIV
PITC in patients
with TB
symptoms
Cough any
duration or
other
symptoms
Not described 28,568 3,029 (10.6) -
Ethiopia, Deribew
(2010) [34]
Cross-sectional
study
Evaluation of HIV
PITC in patients
with TB
symptoms
Chronic cough or
other
symptoms
Not described 506 81 (16.0) 233 (46.0)
Ethiopia, Sahle
(2017) [68]
Cross-sectional
study
LAM evaluation
study
Any TB symptom Urinary LAM, LJ
culture
122 21 (17.2) 35 (28.7)
Guinea-Bissau,
Rudolf (2017)
[69]
Prospective
observational
study
Assessing
biomarkers for
predicting
mortality
Cough any
duration or
other
symptoms
Not described 1011 161 (15.9) 101 (10.0)
India, Boehme
(2011) [23]
Cross-sectional
study
Xpert MTB/RIF
evaluation study
Chronic cough or
suspected
MDR TB
Xpert MTB/RIF,
culture (LJ, MGIT,
Ogawa) + species
ID and DST
902 40 (4.4) 108 (12.0)
India, Achanta
(2012) [32]
Cross-sectional
study
Evaluation of HIV
PITC in patients
with TB
symptoms
Cough ≥2 weeks
or other
symptoms
Smear microscopy 2,918 246 (8.4) 407 (13.9)
India, Naik (2012)
[33]
Cross-sectional
study
Evaluation of HIV
PITC in patients
with TB
symptoms
Clinician
identified
Not described 1539 108 (7.0) 100 (6.5)
India, Kumar (2016)
[14]
Cross-sectional
study
Evaluation of HIV
PITC in patients
with TB
symptoms
Patients
submitting
sputum
samples
Not described 115,308 7,559 (6.5) -
Kenya, Kivihya-
Ndugga (2003)
[70]
Cross-sectional
study
Assessing TB
diagnostic
algorithms
Clinician
identified
Microscopy (ZN,
fluorescence) and
culture (LJ)
993 128 (12.9) 554 (55.8)
Kenya, Odhiambo,
(2008) [35]
Cross-sectional
study
Evaluation of HIV
PITC in patients
with TB
symptoms
Any TB symptom smear microscopy 5457 2,988 (54.8) 2,595 (47.6)
Malawi, Munthali
(2006)[71]
Cross-sectional
study
Assessing HIV
prevalence in
patients with TB
symptoms
Chronic cough Not described 145 79 (54.5) 31 (21.4)
Malawi, Nliwasa
(2016) [29]
Cross-sectional
study
TB-LAMP diagnostic
evaluation study
Cough ≥2 weeks Microscopy
(fluorescence,
ZN), LAMP, Xpert
MTB/RIF, culture
(MGIT) + species
ID
273 121 (44.3) 56 (20.5)
South Africa, Mwansa-
Kambafwile (2011)
Cross-sectional
study
Xpert MTB/RIF
evaluation study
Clinician
identified
Microscopy, Xpert
MTB/RIF
1981 1442 (72.8) 271 (18.8)
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Table 2. (Continued)
Country, author,
yeara Study design Study description
Participant
Eligibility criteria
TB diagnosis
algorithm
Participants
with
symptoms HIV prev. TB prev.
n n (%) n (%)
South Africa, Brunet
(2011) [72]
Cross-sectional
study
Assessing HIV and
smoking
prevalence in
patients with TB
symptoms
Clinician
identified
Microscopy and
culture
424 119 (28.1) 286 (67.5)
South Africa, Scott
(2011) [30]
Cross-sectional
study
Xpert MTB/RIF
evaluation study
Clinician
identified
MTBDRplus and the
LCTB assays,
Xpert MTB/RIF
319 220 (69.0) 175 (54.9)
South Africa, Theron
(2011) [73]
Cross-sectional
study
Xpert MTB/RIF
evaluation study
Definition:
clinician
identified
Microscopy
(fluorescence),
Xpert MTB/RIF,
culture (MGIT)
and DST
480 130 (27.1) 232 (48.3)
South Africa,
Hanrahan (2013)
[27]
Prospective
observational
study
Xpert MTB/RIF
evaluation study
Cough any
duration or
other
Smear microscopy,
culture and Xpert
MTB/RIF
641 443 (69.1) 116 (18.1)
South Africa, Cox
(2014)[25]
Pragmatic
Randomized
Trial
Xpert MTB/RIF
evaluation study
Cough any
duration or
other
symptoms
Xpert MTB/RIF,
smear microscopy,
culture, DST
1985 965 (48.6) 424 (21.4)
South Africa,
Geldenhuys (2014)
[74]
Cross-sectional
study
Assessing sputum
collection
methods
Chronic cough or
other
symptoms
Culture used
(MGIT) + species
ID and DST
555 118 (21.3) 105 (18.9)
South Africa, Van Rie
(2014)[37]
Cross-sectional
study
Assessing uptake of
TB screening
Prolonged cough
and weight
loss
Xpert MTB/RIF 1505 933 (62.0) 90 (6.0)
South Africa,
Churchyard (2015)
[24]
Cluster-
randomized
trial
Xpert MTB/RIF
evaluation study
Clinician
identified
Microscopy and
Xpert MTB/RIF
4656 2,206 (47.4) 385 (8.3)
South Africa,
Hanrahan (2015)
[26]
Prospective
observational
study
Xpert MTB/RIF
evaluation study
Cough any
duration or
other
Smear microscopy,
culture and Xpert
MTB/RIF
1861 1,336 (71.8) 204 (11.0)
Uganda, Srikantiah
(2007)[36]
Cross-sectional
study
Assessing HIV
prevalence in
patients with TB
symptoms
Clinician
identified
ZN microscopy plus
CXR
565 238 (42.1) 378 (66.9)
Zambia, Muyoyeta
(2015) [28]
Cross-sectional
study
Xpert MTB/RIF
evaluation study
Cough any
duration
Xpert MTB/RIF,
chest X-ray,
fluorescence
microscopy
13,926 7,190 (52.6) 2,861 (20.5)
Zimbabwe, Dlodlo
(2015)[50]
Cross-sectional
study
Evaluation of HIV
PITC in patients
with TB
symptoms
Cough ≥ 2
weeks
Microscopy, Xpert
MTB/RIF, if HIV
positive
422 297 (70.4) -
Zimbabwe, Munyati
(2004) [75]
Cross-sectional
study
Assess causes of
chronic cough
Chronic cough Microscopy (ZN)
and culture
(LJ) + species ID
544 454 (83.5) 184 (33.8)
Mixed settings
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Table 2. (Continued)
Country, author,
yeara Study design Study description
Participant
Eligibility criteria
TB diagnosis
algorithm
Participants
with
symptoms HIV prev. TB prev.
n n (%) n (%)
Ethiopia, Legesse
(2010) [76]
Cross-sectional
study
Diagnostic
evaluation study
Clinician
identified
Microscopy (ZN)
and culture (LJ)
140 27 (19.3) 37 (26.4)
Ethiopia, Belay
(2015) [77]
Cross-sectional
study
Assessing HIV
prevalence in
patients with TB
symptoms
Chronic cough Microscopy (ZN)
and culture (LJ)
325 82 (34.9) 110 (33.8)
Ghana, Adjei (2006)
[78]
Cross-sectional
study
Assessing HIV
prevalence in
patients with TB
symptoms
Clinician
identified
Microscopy (ZN) 277 128 (46.2) 108 (39.0)
India, Kaur (2011)
[79]
Cross-sectional
study
Assessing HIV
prevalence in
patients with TB
symptoms
Clinician
identified
Sputum smear
microscopy,
culture
618 3 (0.5) 243 (39.3)
Malawi, Van Lettow
(2015) [44]
Prospective
observational
study
Assessing 6 m
outcomes for
inpatients
Definition: adults
in chronic
cough register.
Tests:
microscopy
and chest X-
ray
Routine care HIV
testing
348 191 (54.9) 53 (15.2)
Peru, Boehme
(2011) [23]
Cross-sectional
study
Xpert MTB/RIF
evaluation study
Chronic cough or
suspected
MDR TB
Xpert MTB/RIF,
culture and DST
1845 5 (0.3) 209 (11.3)
Nigeria, Aliyu
(2013)[80]
Cross-sectional
study
Assessing
prevalence of
NTM
Any TB symptom Culture (MGIT, LJ)
and species ID
1603 378 (23.6) 444 (27.7)
Nigeria, Chuks
(2013) [81]
Cross-sectional
study
Assessing HIV
prevalence in
patients with TB
symptoms
Patients
submitting
sputum
microscopy (ZN) 1544 184 (11.9) 237 (15.3)
South Africa,
Boehme (2011)
[23]
Cross-sectional
study
Xpert MTB/RIF
evaluation study
Chronic cough or
suspected
MDR TB
Xpert MTB/RIF,
culture and DST
2522 947 (37.5) 493 (19.5)
Tanzania, Rachow
(2011) [82]
Cross-sectional
study
Diagnostic
evaluation study
of Xpert
Patients with
suspected TB
Microscopy (ZN),
Xpert MTB/RIF
and culture/DST
292 172 (58.9) 146 (50.0)
Tanzania, Mulder
(2017) [45]
Cross-sectional
study
Assessing use of
rats in TB
diagnosis
Patients with
suspected TB
Xpert MTB/RIF and
Culture
771 264 (34.2) 345 (44.7)
Thailand,
Kawkitinarong
(2017) [83]
Cross-sectional
study
Diagnostic
evaluation study
of Xpert
Patients with
suspected TB
Microscopy, Xpert
MTB/RIF and
culture
494 128 (25.9) 355 (71.9)
Thailand, Nanta
(2011) [84]
Cross-sectional
study
Diagnostic
evaluation study
of Xpert
No description ICT-TB tests 401 206 (51.4) 146 (36.4)
Thailand,
Pinyopornpanish
(2015) [85]
Cross-sectional
study
Diagnostic
evaluation study
of Xpert
Patients with
suspected TB
Microscopy, Xpert
MTB/RIF culture
57 15 (26.3) 27 (47.4)
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Table 2. (Continued)
Country, author,
yeara Study design Study description
Participant
Eligibility criteria
TB diagnosis
algorithm
Participants
with
symptoms HIV prev. TB prev.
n n (%) n (%)
Uganda, Boehme
(2011) [23]
Cross-sectional
study
Xpert MTB/RIF
evaluation study
Chronic cough or
suspected
MDR TB
Xpert MTB/RIF,
culture/DST
372 254 (68.3) 147 (39.5)
Hospital inpatients
Botswana, Talbot
(2004) [86]
Cross-sectional
study
Assessing HIV
prevalence in
patients with TB
symptoms
Cough ≥2 weeks Microscopy (ZN),
culture (LJ, MGIT,
blood) + 4
serological TB
tests
465 384 (82.6) 175 (37.6)
Botswana, Morse
(2008) [47]
Cross-sectional
study
Assessing PTB
diagnosis from
different samples
Clinician
identified
fluorescent
microscopy and
culture (LJ,
MGIT)
140 113 (80.7) 57 (40.7)
Malawi, Gawa
(2011) [43]
Cross-sectional
study
TB programme
evaluation study
Clinician
identified
Smear microscopy
and chest X-ray
141 50 (35.5) 11 (7.8)
Nigeria, Hirao
(2007) [87]
Cross-sectional
study
Assessing number of
samples for TB
diagnosis
Cough ≥3 weeks Smear microscopy
and culture
224 106 (47.3) 78 (34.8)
South Africa, Shah
(2009) [88]
Cross-sectional
study
LAM diagnostic
evaluation study
Patients with
suspected TB
Fluorescent
microscopy, LAM,
culture (MGIT,
MycoF
Lytic) + species
ID
499 422 (84.6) 282 (56.5)
Uganda, Yoon
(2012) [41]
Prospective
observational
study
Evaluation study of
Xpert MTB/RIF
Cough for ≥2
weeks
Florescence
microscopy, Xpert
MTB/RIF, culture
(LJ, MGIT)
+ species ID
477 362 (75.9) 262 (54.9)
Uganda, Jones-
Lopez (2014)
[89]
Cross-sectional
study
Assessing small
membrane
filtration for TB
diagnosis
Cough ≥2 weeks
or other
Fluorescence
microscopy, Xpert
MTB/RIF, culture
(MGIT,
LJ) + species ID
212 173 (81.6) 70 (33.0)
Zambia, O’Grady
(2012) [39]
Cross-sectional
study
Evaluation study of
Xpert MTB/RIF
Patients
submitting
sputum
fluorescent smear
microscopy, Xpert
MTB/RIF, culture
(MGIT) + species
ID
881 595 (67.5) 202 (22.9)
Zambia, Bates
(2013) [38]
Cross-sectional
study
Evaluation study of
Xpert MTB/RIF
Productive cough Microscopy
(fluorescence),
culture (MGIT)
and DST
98 62 (63.3) 26 (26.5)
aSorted by country alphabetical order, for each level of healthcare.
TB, tuberculosis; LJ, Lowenstein-Jensen media; ID, Identification; ZN, Ziehl-Neelsen stain; MGIT, mycobacteria growth indicator tube; DST, drug
susceptibility testing; ICT, immunochromatographic tests; PITC, provider-initiated testing and counselling; NTM, non-tuberculous mycobacteria.
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of previously undiagnosed TB was also substantial, increasing
from 6.9% of adults with TB symptoms identified in the com-
munity to 20.5% and 34.8% in primary care facilities and inpa-
tient units respectively. Patients admitted to hospital with TB
symptoms had a very high risk of short-term mortality (me-
dian 22.6%). These findings emphasize the critical need for
adults identified with TB symptoms in HIV prevalent settings
to be prioritized for HIV testing and ART services, including
adults identified during community outreach or prevalence
surveys. There is also urgent need to better understand and
intervene to reduce short-term mortality in this patient group,
most pressingly so for inpatients, although mortality at
Table 3. Random-effects meta-regression for HIV prevalence in adults with TB symptoms
Studies
Participants
screened
Median HIV
prevalence
Univariate
meta-regression
P
Multivariate
meta-regression
P% (IQR) Prevalence ratio (95% CI) Prevalence ratio (95% CI)
Level of care
Community 12 32,472 19.2 (8.3 to 40.4) 1 1
Primary care 26 139,933 55.7 (20.9 to 71.2) 1.34 (1.11 to 1.61) 0.002 1.32 (1.15 to 1.50) <0.001
Mixed 15 9230 28.6 (21.4 to 52.0) 1.14 (0.93 to 1.40) 0.216 1.29 (1.12 to 1.50) <0.001
Hospital inpatients 9 2966 80.7 (73.8 to 84.6) 1.90 (1.50 to 2.40) <0.001 1.66 (1.40 to 1.97) <0.001
National HIV prevalence
Low (0% to 5%) 25 134,965 17.2 (9.4 to 26.3) 1 1
High (>5%) 37 49,636 62.3 (45.9 to 73.8) 1.56 (1.37 to 1.76) <0.001 1.45 (1.30 to 1.62) <0.001
Group of symptoms
Any TB symptom 41 170,885 32.8 (17.2 to 59.4) 1 1
Chronic cough 21 13,716 68.3 (42.1 to 80.1) 1.24 (1.05 to 1.46) 0.011 1.14 (1.03 to 1.27) 0.013
WHO regiona
Non-Africa region 11 84,658 9.9 (5.1 to 26.1) 1
Africa region 51 99,943 54.5 (26.1 to 70.9) 1.42 (1.16 to 1.72) <0.001
aThere was collinearity between geographical region and country-level HIV prevalence, geographical region was not included in the multivariate
analysis.
Table 4. Random-effects meta-regression for TB prevalence in adults with TB symptoms
Studies
Participants
screened
Median TB
prevalence
Univariate
meta-regression
p
Multivariate
meta-regression
p% (IQR) Prevalence ratio (95% CI) Prevalence ratio (95% CI)
Level of care
Community 12 35,187 6.9 (3.3 to 8.4) 1
Primary care 23 105,234 20.5 (11.5 to 46.8) 1.29 (1.13 to 1.49) <0.001 1.27 (1.11 to 1.46) <0.001
Mixed 15 11,609 36.4 (22.9 to 41.0) 1.42 (1.22 to 1.66) <0.001 1.42 (1.22 to 1.65) <0.001
Hospital inpatients 9 3,137 34.8 (26.5 to 40.7) 1.43 (1.21 to 1.71) <0.001 1.45 (1.22 to 1.72) <0.001
National HIV prevalence
Low (0% to 5%) 24 99,334 23.1 (9.3 to 37.1) 1
High (>5%) 35 55,833 24.1 (11.0 to 44.1) 1.05 (0.93 to 1.19) 0.414
National TB incidence
Moderate/medium
incidence
28 99,014 20.3 (9.1 to 39.1) 1
High incidence 15 36,819 26.5 (17.9 to 41.2) 1.08 (0.94 to 1.26) 0.270
Very high incidence 16 19,334 18.8 (10.3 to 42.6) 1.04 (0.90 to 1.21) 0.562
Symptom group
Any TB symptom 39 138,490 26.4 (9.1 to 46.7) 1 1
Chronic cough 20 16,677 19.9 (11.3 to 33.8) 0.94 (0.83 to 1.07) 0.355 0.94 (0.84 to 1.03) 0.289
WHO region
Non-Africa region 11 67,647 13.9 (9.4 to 37.9) 1
Africa region 48 87,520 22.2 (10.7 to 39.8) 1.05 (0.90 to 1.23) 0.524
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primary care level (3.1% after two to six months follow-up)
was also disturbingly high.
Adults with TB symptoms identified in communities, primary
care settings and in hospitals had median HIV prevalence of
19.2%, 55.7% and 80.7% respectively (Figure 2). National HIV
prevalence was independently associated with higher HIV
prevalence among symptomatic adults in meta-regression. In
Malawi and South Africa, countries with very high national
HIV prevalence, the numbers of adults with TB symptoms
needed to screen (NNS) at community level to detect one
new HIV-positive patient were low at 11 and 4 respectively
[19,48]. In Malawi, the NNS from a single primary care study
was 2, but the current National Strategic Plan for HIV/AIDS
does not prioritize outpatients with TB symptoms for
expanded provider-initiated HIV testing and counselling
(Table 5) [52]. Instead HIV programmes have continued to
focus on established target groups such as young and preg-
nant women, missing the opportunity to combine forces with
TB programmes to provide an essential service for this high
HIV prevalence patient group.
This is the first systematic literature review to estimate the
prevalence of HIV among adults with TB symptoms. However,
other reviews have addressed related subjects. A previous
systematic literature review assessed the diagnostic utility of
symptoms for TB among people with HIV [3]. This review
reported that the best performing rule was the presence of
any one of: current cough (any duration), fever, night sweats
or weight loss with sensitivity of 78.9% (95% CI 58.3% to
90.9%) and specificity of 49.6% (95% CI 29.2% to 70.1%) [3].
Another systematic literature review highlighted the impor-
tance of respiratory symptoms among HIV-positive individuals
[53], with a pooled odds ratio for the prevalence of cough of
3.05 (95% CI 2.24 to 4.16) among HIV-positive compared to
HIV-negative individuals [53]. HIV-positive people remain at
higher risk of respiratory symptoms even when started on
ART, and are at increased risk of chronic lung disease from a
variety of causes [54]. Ideally, advice on smoking cessation
and links to specialist services providing diagnosis and man-
agement of infectious and non-infectious causes of lung dis-
ease should be included as part of routine HIV care, along
with regular screening for TB [53].
As discussed above, our TB prevalence and mortality find-
ings are not representative of low HIV prevalence settings.
Within this limitation, however, we show the level of health-
care at which adults with TB symptoms present to be an
important determinant of expected yield of TB on further
screening. The median prevalence of undiagnosed TB was
6.9% for symptomatic adults identified at community level,
20.5% at primary care level and 34.8% for inpatients (Fig-
ure 2). At community as well as facility level, TB screening
using symptoms and chest radiography combined with HIV
testing for all with suspected TB, could then make an impor-
tant contribution to early TB diagnosis as well as simultane-
ously providing HIV programmes with high yields of previously
undiagnosed HIV. Oral kits packaged for HIV self-testing pro-
vide safe, accurate and highly acceptable access to HIV diag-
nosis that can more easily be integrated into high-throughput
TB screening programmes than standard HIV testing services
[55]. Community-based TB screening can lead to rapid reduc-
tion in undiagnosed infectious TB by reaching people who
may otherwise remain undiagnosed for prolonged periods,
potentially averting deaths and post-tuberculous disability
[56,57].
The risk of early mortality among adults with TB symptoms
also increased substantially with level of care at presentation,
but with the major step-up for this outcome at inpatient level.
Death within two to six months of follow-up was reported for
1.6% with TB symptoms at community level, 3.1% at primary
care and 22.6% among hospital inpatients (Figure 2). All stud-
ies contributing to these estimates were from high HIV preva-
lence settings. The largest contributing study, conducted in
outpatient facilities in South Africa, reported a threefold
increase in the risk of death at six months for HIV-positive
compared to HIV-patients are prompt HIV testing and linkage
to cotrimoxazole and ART [58,59] plus rapid diagnosis of TB
disease, including use of urine lipoarabinomannan assay for
HIV-positive inpatients, followed by prompt TB treatment
(n = 5)
Hospital 
inpatients
(n = 1)
Mixed
(n = 4)
Primary care
(n = 1)
Community
(n = 9)
Hospital 
inpatients
(n = 15)
Mixed
(n = 23)
Primary care
Community
(n = 12)
Mixed
(n = 9)
(n = 26)
Primary care
Community
(n = 12)
HIV prevalence (%)
0 25 50 75 100
Hospital 
inpatients
Le
ve
l o
f c
ar
e
TB prevalence (%)
Le
ve
l o
f c
ar
e
0 25 50 75 100
Mortality risk (%)
(n = 15)
Le
ve
l o
f c
ar
e
0 25 50 75 100
19.2%
55.7%
28.6%
80.7%
6.9%
20.5%
36.4%
34.8%
1.6%
3.1%
10.9%
22.6%
Figure 2. Summary HIV prevalence, TB prevalence and mortality
risk at six months.
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(Table 5) [60,61]. With mortality at such unacceptably high
levels for such a common clinical presentation, intensified
research and programmatic efforts aimed at reducing this risk
should be of the highest priority, including intensified TB
screening approaches, prophylactic broad-spectrum antibiotics
and host-directed therapies (Table 5) [62,63].
Limitations to this study include those that relate to selec-
tion of studies and those relating to approaches of analysis.
There was the pronounced under-representation of studies
from low HIV as well as low TB prevalence settings. The
included studies, mostly from high HIV prevalence settings,
also potentially had different coverage of ART, and ART is
Table 5. Recommendations and future directions
Identified problem Research directions Programme priorities References
Community level
High HIV prevalence among
adults with cough
Cluster randomized controlled
trials to increase access to HIV
testing in the community
Implement initiatives to achieve UNAIDS 90-90-90
targets: Community strategies, e.g. home-based or
mobile HIV testing and HIV self-testing (HIVST)
[55, 90,91]
High prevalence of undiagnosed
TB and delayed access to
care in community
Randomized controlled trials
(RCT) to investigate effective
TB diagnostic algorithms, e.g.
use of digital chest X-ray
screening
Implement active TB case finding in communities
including community-led initiatives
[92-94]
Few studies investigating risk of
death associated with
respiratory symptoms at
community
Prospective studies investigating
risk of death and risk factors
and RCTs to modify risk of
death
Mortality surveys nested in
longitudinal DHS sites
Improve death registration by setting-up vital
registration systems
[95]
Primary care
High HIV prevalence among
adults with cough
Operational research to achieve
high coverage of accurate
provider-initiated testing and
counselling
HIV testing for all health facility attendees
Immediate ART initiation in accordance with guidelines
and improve retention in care
[5,96]
High TB prevalence among
adults with cough
RCTs to investigate algorithms for
TB screening, e.g. those that
include Xpert MTB/RIF and
digital chest radiography
TB screening for all health facility attendees for
infection control and to improve care of
patientsSystematic TB screening using of digital
chest X-ray screening and Xpert MTB/RIF
[5]
High risk of death among adults
with cough
RCTs to investigate impact of new
TB diagnostic tests to reduce
risk of early death, potentially
Xpert MTB/RIF Ultra
Operational recommendations are early HIV diagnosis,
immediate ART and cotrimoxazole prophylaxis, and
isoniazid preventive therapy if HIV positive
[96,97]
Hospital
Very high HIV prevalence
among adults with cough
Operational research to achieve
high coverage of accurate PITC
HIV testing for all health facility attendees
Immediate ART initiation in accordance with guidelines
and improve retention in care
[5,96]
Very high TB prevalence among
adults with cough
RCTs to investigate algorithms for
TB screening in hospitals that
include Xpert MTB/RIF and
digital chest radiography
TB screening for all health facility attendees for
infection control and to improve care of patients
Isolation to reduce nosocomial spread
[5]
Very high risk of early death RCTs to investigate impact of new
TB diagnostic tests to reduce
risk of early death, potentially
Xpert MTB/RIF Ultra
RCTs to investigate effect of
antibiotics, nutrition and host-
directed therapies
Operational recommendations are early HIV diagnosis,
immediate ART and cotrimoxazole prophylaxis, and
isoniazid preventive therapy if HIV positive
Use of urinary LAM to screen all HIV-positive
individuals for disseminated TB
[60, 96,97]
TB, tuberculosis; DHS, demographic and health survey; ART, antiretroviral therapy; LAM, lipoarabinomannan; HIVST, HIV self-testing.
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likely to reduce prevalence of TB and also prevalence of TB
symptoms. Due to our inclusion criteria, estimates of TB
prevalence were limited to studies that also conducted HIV
testing, thereby excluding most TB prevalence surveys. We
only included studies published in English language; this may
bias our estimates. There was considerable heterogeneity that
was found in meta-analyses for all three outcomes that could
not be explained by differences in type of participants, geo-
graphical region or background burden of HIV and TB. There-
fore, summary estimates from meta-analyses were not
presented. This may also be partly because statistical tests for
heterogeneity do not work well with pooled proportions [64].
In conclusion, the findings from this systematic literature
review illustrate the urgent need to improve the management
of patients with TB symptoms in high HIV prevalence settings.
HIV prevalence among adults with TB symptoms was high at
all levels of healthcare, including in general population surveys,
while TB prevalence and mortality risk increased substantially
at primary care and hospital level respectively. The high yield
of undiagnosed HIV should make both community- and facil-
ity-based TB screening interventions of high interest to HIV
programmes trying to reach UNAIDS 90-90-90 targets for
HIV service coverage. TB programmes need to develop the
necessary partnerships and expertise to ensure that HIV test-
ing is provided alongside all TB screening interventions. More
usable and effective high-throughput TB screening algorithms
are needed at all levels of the health system. The high risk of
early death, most notable for inpatients, but also at primary
care is an issue in urgent need of more research and interven-
tion. Annual reporting to WHO of the coverage of HIV testing,
yield of HIV, linkage to ART and treatment outcomes among
people investigated for TB would increase the international
visibility of this important patient group, encourage national
programmes to implement existing international recommenda-
tions, and enable progress to be tracked over time.
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